Lantern Pharma Inc.
LTRN
$4.44
-$0.13-2.85%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -8.46% | -13.36% | -30.19% | -25.96% | -24.46% |
| Total Depreciation and Amortization | 16.28% | -11.23% | -38.50% | 45.45% | 16.91% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -15.46% | -45.10% | -29.89% | -111.18% | -75.97% |
| Change in Net Operating Assets | -55.92% | -94.28% | 314.16% | 4,488.49% | 223.90% |
| Cash from Operations | -17.11% | -39.99% | -24.16% | -26.39% | -8.54% |
| Capital Expenditure | 55.49% | 4.13% | 32.98% | 29.47% | 27.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,417.87% | 1,497.82% | 471.07% | 134.27% | 70.71% |
| Cash from Investing | 4,153.29% | 1,463.43% | 462.21% | 130.54% | 69.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -78.06% | -78.06% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 102.69% | 102.69% | 113.34% | -- | -- |
| Foreign Exchange rate Adjustments | -30.97% | -11.14% | -74.30% | 194.16% | -354.10% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.75% | 18.29% | 8.72% | -22.78% | -7.02% |